Dupont Capital Management Corp decreased its holdings in Glaukos Corporation (NYSE:GKOS) by 40.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,540 shares of the medical instruments supplier’s stock after selling 9,234 shares during the quarter. Dupont Capital Management Corp’s holdings in Glaukos Corporation were worth $447,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the company. Janus Henderson Group PLC acquired a new stake in shares of Glaukos Corporation in the 2nd quarter worth $129,356,000. Capital World Investors boosted its position in shares of Glaukos Corporation by 17.1% in the 2nd quarter. Capital World Investors now owns 2,740,000 shares of the medical instruments supplier’s stock worth $113,628,000 after purchasing an additional 400,000 shares in the last quarter. William Blair Investment Management LLC boosted its position in shares of Glaukos Corporation by 4.9% in the 2nd quarter. William Blair Investment Management LLC now owns 2,164,764 shares of the medical instruments supplier’s stock worth $89,773,000 after purchasing an additional 100,320 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Glaukos Corporation by 3.4% in the 2nd quarter. Vanguard Group Inc. now owns 1,668,345 shares of the medical instruments supplier’s stock worth $69,187,000 after purchasing an additional 55,507 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its position in shares of Glaukos Corporation by 26.7% in the 2nd quarter. Alliancebernstein L.P. now owns 1,636,621 shares of the medical instruments supplier’s stock worth $67,871,000 after purchasing an additional 344,739 shares in the last quarter.

Shares of Glaukos Corporation (NYSE GKOS) opened at $30.09 on Monday. Glaukos Corporation has a 52-week low of $28.72 and a 52-week high of $52.49. The company has a market capitalization of $1,040.07, a PE ratio of 250.75 and a beta of 1.25.

Glaukos Corporation (NYSE:GKOS) last issued its quarterly earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.04 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.02) by $0.06. Glaukos Corporation had a positive return on equity of 3.50% and a negative net margin of 0.64%. The company had revenue of $40.41 million during the quarter, compared to analysts’ expectations of $38.69 million. During the same quarter in the previous year, the firm posted $0.03 EPS. The firm’s revenue was up 36.6% compared to the same quarter last year. research analysts predict that Glaukos Corporation will post -0.02 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This news story was published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.watchlistnews.com/glaukos-corporation-gkos-stake-decreased-by-dupont-capital-management-corp/1699886.html.

GKOS has been the subject of a number of recent analyst reports. Cantor Fitzgerald reissued a “buy” rating and issued a $60.00 price objective on shares of Glaukos Corporation in a research report on Tuesday, November 7th. BMO Capital Markets lowered their price target on Glaukos Corporation from $45.00 to $40.00 and set an “outperform” rating for the company in a research report on Wednesday, November 8th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $56.00 price target on shares of Glaukos Corporation in a research report on Thursday, August 3rd. Stephens reaffirmed an “overweight” rating and set a $40.00 price target (down previously from $47.00) on shares of Glaukos Corporation in a research report on Monday. Finally, BidaskClub raised Glaukos Corporation from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. Glaukos Corporation currently has a consensus rating of “Buy” and a consensus target price of $46.86.

In other Glaukos Corporation news, Director Orbimed Advisors Llc sold 580,200 shares of Glaukos Corporation stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $38.73, for a total transaction of $22,471,146.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Thomas William Burns sold 73,788 shares of Glaukos Corporation stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $41.36, for a total value of $3,051,871.68. The disclosure for this sale can be found here. Insiders have sold a total of 980,200 shares of company stock valued at $37,900,263 in the last quarter. Company insiders own 16.40% of the company’s stock.

Glaukos Corporation Company Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS).

Institutional Ownership by Quarter for Glaukos Corporation (NYSE:GKOS)

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.